0001415889-25-010640.txt : 20250414 0001415889-25-010640.hdr.sgml : 20250414 20250414181315 ACCESSION NUMBER: 0001415889-25-010640 CONFORMED SUBMISSION TYPE: SCHEDULE 13G PUBLIC DOCUMENT COUNT: 2 FILED AS OF DATE: 20250414 DATE AS OF CHANGE: 20250414 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: Inventiva S.A. CENTRAL INDEX KEY: 0001756594 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 000000000 STATE OF INCORPORATION: I0 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SCHEDULE 13G SEC ACT: 1934 Act SEC FILE NUMBER: 005-91576 FILM NUMBER: 25837047 BUSINESS ADDRESS: STREET 1: 50 RUE DE DIJON CITY: DAIX STATE: I0 ZIP: 21121 BUSINESS PHONE: 33380447500 MAIL ADDRESS: STREET 1: 50 RUE DE DIJON CITY: DAIX STATE: I0 ZIP: 21121 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: Andera Partners CENTRAL INDEX KEY: 0001757283 ORGANIZATION NAME: EIN: 000000000 STATE OF INCORPORATION: I0 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SCHEDULE 13G BUSINESS ADDRESS: STREET 1: 374 RUE SAINT ST HONORE CITY: PARIS STATE: I0 ZIP: 75001 BUSINESS PHONE: 33-1-85-73-6603 MAIL ADDRESS: STREET 1: 374 RUE SAINT ST HONORE CITY: PARIS STATE: I0 ZIP: 75001 SCHEDULE 13G 1 primary_doc.xml SCHEDULE 13G 0001757283 XXXXXXXX LIVE Ordinary Shares, nominal value Euro 0.01 per share 10/17/2024 0001756594 Inventiva S.A. 46124U107 50 rue de Dijon Daix I0 21121 Rule 13d-1(c) Andera Partners I0 0.00 6148147.00 0.00 6148147.00 6148147.00 6.5 OO BioDiscovery 6 FPCI I0 0.00 6148147.00 0.00 6148147.00 6148147.00 6.5 OO Stephane Bergez I0 0.00 6148147.00 0.00 6148147.00 6148147.00 6.5 IN Francois Xavier Mauron I0 0.00 6148147.00 0.00 6148147.00 6148147.00 6.5 IN Inventiva S.A. 50 rue de Dijon, Daix, I0, 21121 . The names of the persons filing this report (collectively, the "Reporting Persons") are: BioDiscovery 6 FPCI ("BioDiscovery 6") Andera Partners ("Andera") Stephane Bergez ("Bergez") Francois Xavier Mauron ("Mauron") The Reporting Persons expressly disclaim status as a "group" for purposes of this Schedule 13G. 2 place de Rio de Janeiro 75008 Paris France BioDiscovery 6 France Andera France Bergez France Mauron France Y Row 9 of each Reporting Person's cover page to this Schedule 13G sets forth the aggregate number of securities of the Issuer beneficially owned by such Reporting Person as of the date hereof and is incorporated by reference. BioDiscovery 6 is the record holder of 6,148,147 ordinary shares. Voting and dispositive decisions with respect to the securities held by BioDiscovery 6 are made by its management company, Andera. The managing partners of Andera are Bergez and Mauron. As a result, each of the Reporting Persons may be deemed to beneficially own the securities held by BioDiscovery 6. CUSIP Number 46124U107 has been assigned to the American Depositary Shares ("ADS") of the Issuer, which are quoted on the Nasdaq Global Market under the symbol "IVA". Each ADS represents one ordinary share of the Issuer. No CUSIP has been assigned to the Issuer's ordinary shares. Row 11 of each Reporting Person's cover page to this Schedule 13G sets forth the percentages of the securities of the Issuer beneficially owned by such Reporting Person as of the date hereof and is incorporated by reference. The percentage set forth in each row 11 is based upon 94,949,759 ordinary shares outstanding as of December 19, 2024, as reported in the Issuer's Report of Foreign Private Issuer on Form 6-K filed with the Securities and Exchange Commission (the "SEC") on December 16, 2024. Row 5 of each Reporting Person's cover page to this Schedule 13G sets forth the sole power to vote or to direct the vote of securities of the Issuer beneficially owned by such Reporting Person as of the date hereof and is incorporated by reference. Row 6 of each Reporting Person's cover page to this Schedule 13G sets forth the shared power to vote or to direct the vote of securities of the Issuer beneficially owned by such Reporting Person as of the date hereof and is incorporated by reference. Row 7 of each Reporting Person's cover page to this Schedule 13G sets forth the sole power to dispose or to direct the disposition of securities of the Issuer beneficially owned by such Reporting Person as of the date hereof and is incorporated by reference. Row 8 of each Reporting Person's cover page to this Schedule 13G sets forth the shared power to dispose or to direct the disposition of securities of the Issuer beneficially owned by such Reporting Person as of the date hereof and is incorporated by reference. Y Y Y Y Y N By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. Exhibit 99.1 Joint Filing Agreement Andera Partners /s/ Stephane Bergez By Stephane Bergez, Managing Partner 04/14/2025 BioDiscovery 6 FPCI /s/ Stephane Bergez By Andera Partners, its management company, By Stephane Bergez, Managing Partner 04/14/2025 Stephane Bergez /s/ Stephane Bergez Stephane Bergez 04/14/2025 Francois Xavier Mauron /s/ Francois Xavier Mauron Francois Xavier Mauron 04/14/2025 EX-99.1 2 ex-99-04142025_100413.htm JOINT FILING AGREEMENT ex-99-04142025_100413.htm

EXHIBIT 99.1

JOINT FILING AGREEMENT

In accordance with Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree that they are jointly filing the attached Schedule 13G (or any amendments thereto) relating to the ordinary shares of Inventiva S.A. Each of them is responsible for the timely filing of such statement and any amendments thereto, and for the completeness and accuracy of the information concerning such person contained therein; but none of them is responsible for the completeness or accuracy of the information concerning the other persons making the filing, unless such person knows or has reason to believe that such information is inaccurate.


IN WITNESS WHEREOF, the undersigned hereby execute this Joint Filing Agreement as April 14, 2025.


Andera Partners


By:

/s/ Stephane Bergez

Name: Stephane Bergez

Title: Managing Partner



BioDiscovery 6 FPCI


By:

Andera Partners

Its:

Management Company



By:

/s/ Stephane Bergez

Name: Stephane Bergez

Title: Managing Partner



Stephane Bergez


/s/ Stephane Bergez




François Xavier Mauron


/s/ François Xavier Mauron